Physician profile
Tara Amini
NPI 1508079906
$10,455.32
in general payments reported to CMS, 2019-2025
36 companies · $5,904 in 2025
The $5,904 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,005 · 2024: $3,546 · 2025: $5,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,397.50 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,808.15 | 2023-2025 | |
| Gilead Sciences, INC. | $1,428.57 | 2023-2025 | Epclusa, Vemlidy, Yeztugo |
| Amgen INC. | $860.25 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $710.39 | 2024-2025 | Wegovy, Ozempic |
| Viiv Healthcare Company | $617.44 | 2024-2025 | Apretude, Cabenuva |
| Regeneron Healthcare Solutions, INC. | $506.02 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $448.54 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Acadia Pharmaceuticals INC | $301.64 | 2024-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $278.89 | 2024 | Ingrezza |
| Madrigal Pharmaceuticals | $266.68 | 2025 | Rezdiffra |
| Abiomed | $230.89 | 2024-2025 | Impella |
| Dynavax Technologies Corporation | $219.83 | 2023-2025 | Heplisav-B |
| Exact Sciences Corporation | $217.89 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Indivior INC. | $209.85 | 2023-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $205.10 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $199.70 | 2024-2025 | Brixadi |
| Lilly USA, LLC | $178.10 | 2024-2025 | Mounjaro, Zepbound |
| Insmed, INC. | $170.11 | 2025 | Arikayce, Brinsupri |
| Verrica Pharmaceuticals INC. | $159.72 | 2024-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $156.69 | 2024-2025 | |
| Ardelyx, INC. | $142.91 | 2025 | Ibsrela |
| Sk Life Science, INC. | $125.00 | 2025 | Xcopri |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Eisai INC. | $122.06 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $121.81 | 2025 | Iqirvo |
| Shield Therapeutics INC | $120.75 | 2024-2025 | |
| Genzyme Corporation | $112.49 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $111.37 | 2025 | |
| Axsome Therapeutics, INC. | $86.11 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $64.63 | 2024 | |
| Novartis Pharmaceuticals Corporation | $42.16 | 2023 | |
| Cranial Technologies, INC | $36.29 | 2023-2025 | Doc Band |
| Qiagen, LLC | $22.36 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.87 | 2025 | Xifaxan |
| Pfizer INC. | $15.34 | 2024 | |
| Abbott Laboratories | $14.09 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Amini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.